Metabolic syndrome is a significant worldwide public health challenge and is inextricably linked to adverse renal and cardiovascular outcomes. The inhibition of the
transient receptor potential cation channel subfamily C member 6 (
TRPC6) has been found to ameliorate renal outcomes in the unilateral
ureteral obstruction (UUO) of accelerated renal
fibrosis. Therefore, the pharmacological inhibition of TPRC6 could be a promising therapeutic intervention in the progressive tubulo-interstitial
fibrosis in
hypertension and
metabolic syndrome. In the present study, we hypothesized that the novel selective
TRPC6 inhibitor
SH045 (
larixyl N-methylcarbamate) ameliorates UUO-accelerated renal
fibrosis in a New Zealand obese (NZO) mouse model, which is a polygenic model of
metabolic syndrome. The in vivo inhibition of
TRPC6 by
SH045 markedly decreased the
mRNA expression of pro-fibrotic markers (Col1α1, Col3α1, Col4α1, Acta2, Ccn2, Fn1) and
chemokines (Cxcl1, Ccl5, Ccr2) in UUO kidneys of NZO mice compared to kidneys of vehicle-treated animals. Renal expressions of
intercellular adhesion molecule 1 (ICAM-1) and α-smooth muscle actin (α-SMA) were diminished in SH045- versus vehicle-treated UUO mice. Furthermore, renal inflammatory cell infiltration (F4/80+ and CD4+) and tubulointerstitial
fibrosis (Sirius red and
fibronectin staining) were ameliorated in SH045-treated NZO mice. We conclude that the pharmacological inhibition of
TRPC6 might be a promising antifibrotic therapeutic method to treat progressive tubulo-interstitial
fibrosis in
hypertension and
metabolic syndrome.